Sopharma proposes EUR 0.05 interim dividend for Sopharma stock

Published on 10/14/2026 at 04:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The proposal covers EUR 0.05 per share on September 26, 2026. Sopharma stock saw sales rise 11.00 percent to EUR 730.00 million in the first half of 2026.

Dividend and reporting dates

On September 26, 2026, Sopharma disclosed a proposed EUR 0.05 interim dividend per share.
First-half sales increased 11.00 percent to EUR 730.00 million.
Sopharma shareholders are scheduled to vote on October 30, 2026.

Sopharma, BG11SOSOBT18, Illustration mit AI erstellt.

Sopharma (BG11SOSOBT18) proposed a EUR 0.05 interim dividend per share on September 26, 2026, according to Investor.bg. The proposal puts the October shareholder meeting at the center of the stock story, while the latest reported figures provide the earnings backdrop.

Three dated milestones

On August 28, 2026, Sopharma's latest reported release showed revenue of EUR 374.54 million, according to Investing.com. On September 25, 2026, the company published materials for a shareholder meeting covering approval of the six-month report and an interim dividend, as reported by PB.pl. On September 26, 2026, Investor.bg reported the proposed EUR 0.05 per-share payment.

What does the dividend proposal add?

The proposed distribution is tied to Sopharma's first-half performance. Investor.bg reported consolidated first-half net profit of EUR 50.80 million, up 41.00 percent year over year, while consolidated sales increased 11.00 percent to EUR 730.00 million.

The same proposal represents a potential total distribution of EUR 28.00 million if all eligible shares receive the payment, Investor.bg reported. That comparison matters because the dividend decision is being considered alongside the six-month financial report rather than as a standalone capital-return announcement.

Shareholder dates set the timetable

Sopharma's extraordinary general meeting is scheduled for October 30, 2026, in Sofia, with approval of the six-month report and the interim dividend on the agenda, according to PB.pl. A reserve date of November 20, 2026, was reported by Stockd.

Profit growth sets the backdrop

The 41.00 percent first-half net-profit increase to EUR 50.80 million gives the proposed payment a reported earnings base, while 11.00 percent sales growth to EUR 730.00 million points to expansion on the top line. Sopharma produces, distributes and exports pharmaceutical products, with its BGSFA ticker and Sofia listing identified by Investing.com.